Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucie Hamel

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Prostate|September 2, 2011
Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and menMaurice Anidjar, Eleonora Scarlata, Fabio L Cury, et al.
Molecular Cancer Research : MCR|January 17, 2009
The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growthAmina Zoubeidi, Joice Rocha, Fatima Z Zouanat, et al.
The Journal of Urology|May 24, 2011
Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostateSimone Chevalier, Maurice Anidjar, Eleonora Scarlata, et al.
Molecular and Cellular Endocrinology|August 3, 2013
The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancerJoice Rocha, Fatima Z Zouanat, Amina Zoubeidi, et al.
The Journal of Pathology. Clinical Research|April 19, 2023
Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progressionSeta Derderian, Tarik Benidir, Eleonora Scarlata, et al.
Clinical and Translational Science|September 29, 2022
Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancerSeta Derderian, Quentin Vesval, Michel D Wissing, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 25, 2018
The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomyYogesh M Bramhecha, Shaghayegh Rouzbeh, Karl-Philippe Guérard, et al.
BMC Urology|July 26, 2019
Improving ultrasound-based prostate volume estimationSaro Aprikian, Murilo Luz, Fadi Brimo, et al.
Molecular Cancer Research : MCR|October 11, 2017
Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical InterventionYogesh M Bramhecha, Karl-Philippe Guérard, Shaghayegh Rouzbeh, et al.
Biopreservation and Biobanking|November 7, 2013
Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer BiobankFadi Brimo, Armen Aprikian, Mathieu Latour, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Prostate|September 2, 2011
Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and menMaurice Anidjar, Eleonora Scarlata, Fabio L Cury, et al.
Molecular Cancer Research : MCR|January 17, 2009
The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growthAmina Zoubeidi, Joice Rocha, Fatima Z Zouanat, et al.
The Journal of Urology|May 24, 2011
Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostateSimone Chevalier, Maurice Anidjar, Eleonora Scarlata, et al.
Molecular and Cellular Endocrinology|August 3, 2013
The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancerJoice Rocha, Fatima Z Zouanat, Amina Zoubeidi, et al.
The Journal of Pathology. Clinical Research|April 19, 2023
Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progressionSeta Derderian, Tarik Benidir, Eleonora Scarlata, et al.
Clinical and Translational Science|September 29, 2022
Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancerSeta Derderian, Quentin Vesval, Michel D Wissing, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 25, 2018
The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomyYogesh M Bramhecha, Shaghayegh Rouzbeh, Karl-Philippe Guérard, et al.
BMC Urology|July 26, 2019
Improving ultrasound-based prostate volume estimationSaro Aprikian, Murilo Luz, Fadi Brimo, et al.
Molecular Cancer Research : MCR|October 11, 2017
Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical InterventionYogesh M Bramhecha, Karl-Philippe Guérard, Shaghayegh Rouzbeh, et al.
Biopreservation and Biobanking|November 7, 2013
Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer BiobankFadi Brimo, Armen Aprikian, Mathieu Latour, et al.
Pageof 2